Target and Technology
SGN-CD352A is an antibody-drug conjugate (ADC) directed against the immunoreceptor CD352. CD352 is a newly described multiple myeloma tumor protein that is broadly expressed on B-cell malignancies including multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma, but narrowly expressed on normal lymphocytes. It uses our proprietary ADC technology, which attaches the anti-CD352 antibody to two molecules of a highly potent DNA crosslinking agent called a PBD (pyrrolobenzodiazepine) dimer using a stable linker.
ADC technology combines the specificity of monoclonal antibodies, innovative linker systems, and the cell killing power of potent cytotoxic agents to treat cancer. Using our proprietary industry-leading technology, we are able to optimize each ADC to potentially improve outcomes for patients.
Clinical Development Status
- Phase 1 trial evaluating the safety and antitumor activity of SGN-CD352A in patients with multiple myeloma
Proposed Mechanism of Action
SGN-CD352A is an investigational agent, and its safety and efficacy have not yet been established.